LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2025
0mins
Source: Globenewswire
Clinical Trial Update: LIXTE Biotechnology has initiated a clinical trial at the Lurie Cancer Center, combining its drug LB-100 with GSK's immunotherapy Dostarlimab to treat ovarian clear cell cancer, with the first patient already dosed.
Company Overview: LIXTE is focused on developing innovative cancer therapies and has demonstrated that LB-100 is well-tolerated in patients, potentially enhancing outcomes when used alongside existing treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
